Companies › VTGN

VISTAGEN THERAPEUTICS INC (VTGN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001411685 · EDGAR filings · Updated 2026-07-02

VISTAGEN THERAPEUTICS INC (VTGN) has reported institutional ownership of 35.9%, with 56 institutional managers holding positions valued at $8.12M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-06-30 — Current report (8-K) filed
• 2026-06-17 — Current report (8-K) filed
• 2026-06-15 — Annual report (10-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, VISTAGEN THERAPEUTICS INC has 56 institutional holders and institutional ownership of 35.9%.

Insider activity

Insiders reported 5 transactions (0 buys, 0 sells) across 4 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

RENOVORX INC (RNXT) · Bausch Lomb Corp (BLCO) · SS INNOVATIONS INTERNATIONAL COM NEW (SSII) · TherapeuticsMD Inc (TXMD) · VYNE THERAPEUTICS INC (VYNE) · QUOIN PHARMACEUTICALS LTD (QNRX)